Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 222 Carcinoma, Renal Cell 84 Liver Neoplasms 68 Neoplasms 53 Leukemia, Myeloid, Acute 37 Neoplasm Metastasis 34 Carcinoma, Non-Small-Cell Lung 33 Breast Neoplasms 29 Melanoma 24 Kidney Neoplasms 22 Pancreatic Neoplasms 16 Brain Neoplasms 15 Sarcoma 14 Prostatic Neoplasms 14 Lung Neoplasms 14 Thyroid Neoplasms 13 Recurrence 13 Glioblastoma 13 Colorectal Neoplasms 12 Carcinoma 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Urinary Bladder Neoplasms 8 Rectal Neoplasms 8 Ovarian Neoplasms 8 Myelodysplastic Syndromes 8 Multiple Myeloma 8 Gliosarcoma 8 Stomach Neoplasms 7 Colonic Neoplasms 7 Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 temsirolimus 1 satraplatin 1 ridaforolimus 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancers × Sorafenib × Clear all

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡